Business Context and Reporting Period
Company: MacroGenics, Inc. (MGNX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including antibody-drug conjugates (ADCs) and multi-specific antibodies (DART and TRIDENT molecules). The company operates a commercial-scale cGMP manufacturing facility and provides contract development and manufacturing services (CDMO) to offset operating costs. Key proprietary candidates include lorigerlimab, MGC026, and MGC028.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $20.8 million | $13.2 million |
| Net Loss | $(36.8) million | $(41.0) million |
| Net Loss Per Share (Basic & Diluted) | $(0.58) | $(0.65) |
| Operating Cash Flow | $(35.8) million | $(46.9) million |
| Cash & Cash Equivalents (End of Period) | $66.5 million | $145.6 million |
| Marketable Securities | $87.7 million | $132.7 million |
| Total Assets | $217.9 million | $256.8 million |
| Total Liabilities | $196.7 million | $201.3 million |
| Stockholders' Equity | $21.2 million | $55.6 million |
Revenue Breakdown (Q1 2026): Contract manufacturing ($14.1M), Royalty revenue ($6.2M), Collaborative and other agreements ($0.6M).
Expense Breakdown (Q1 2026): R&D ($35.0M), Cost of manufacturing services ($9.5M), G&A ($9.7M).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 58% to $20.8 million, driven by a 126% increase in contract manufacturing revenue ($7.8M increase) due to higher production volumes and a significant increase in royalty revenue ($5.8M increase) from higher sales of ZYNYZ. This was partially offset by a 91% decrease in collaborative revenue.
- Net Loss Improvement: Net loss narrowed by $4.3 million (10%) to $36.8 million, primarily due to reduced R&D expenses.
- R&D Expense Reduction: Total R&D expenses decreased 12% to $35.0 million. This was largely due to the discontinuation of the vobramitamab duocarmazine program (costs down $7.9M) and reduced preclinical ADC costs. Increases in costs for MGC028 and next-generation T-cell engagers partially offset these savings.
- Liquidity Position: Cash and cash equivalents decreased by $9.3 million during the quarter, though total liquid assets (cash + marketable securities) remain at $154.2 million. The company utilized net cash from investing activities ($45.3M) primarily from maturities of marketable securities.
- Liability Structure: Deferred revenue increased significantly to $68.0 million (from $10.9M in Q1 2025) due to new manufacturing agreements and option exercises, while the "Liability related to future royalties" decreased to $68.7 million following royalty monetization accounting adjustments.
Guidance, Outlook, and Material Events
- Subsequent Event - CDMO Sale: On May 11, 2026, the company entered an agreement to sell its CDMO operations to Bora Pharmaceuticals for $122.5 million in cash, subject to adjustments. The transaction is expected to close in Q3 2026. This sale is intended to reduce costs and focus resources on the clinical pipeline.
- Subsequent Event - Royalty Monetization: On May 1, 2026, the company amended its royalty purchase agreement with Sagard, receiving an additional $60.0 million payment. The aggregate purchase price is now $130.0 million.
- Liquidity Outlook: Management states that current resources, combined with the $60M Sagard payment and the anticipated $122.5M from the CDMO sale, support a cash runway through 2028.
- Risks: Key risks include the uncertainty of closing the CDMO sale, reliance on third-party manufacturers post-sale, clinical trial outcomes, and the ability to raise additional capital if needed. The company notes that failure to close the CDMO transaction could adversely affect the stock price and business operations.
- Cost Reduction: The company is executing cost-saving measures to extend its financial runway while advancing its pipeline.
Investor Verification Checklist
- CDMO Transaction Closing: Verify the status of the $122.5 million sale to Bora Pharmaceuticals and the satisfaction of closing conditions (e.g., landlord consent).
- Manufacturing Transition: Confirm the terms of the new manufacturing and supply agreement with Bora to ensure continuity of clinical supply for proprietary candidates.
- Royalty Monetization Terms: Review the amended agreement with Sagard regarding the $130M aggregate purchase price and the revised royalty cap (1.70x by 2032 or 2.0x thereafter).
- Cash Runway Validation: Assess the accuracy of the 2028 cash runway projection given the timing of the CDMO sale proceeds and ongoing R&D burn rates.
- Clinical Progress: Monitor upcoming data readouts for key candidates lorigerlimab, MGC026, and MGC028, which drive future milestone potential.